AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8799512
Drug: Nifedipine (NIF)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (NIF) 20 mg twice daily
Trial: 1459316
Drug: benazepril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril (10 mg/day)
Trial: 15931690
Drug: Oral famciclovir
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral famciclovir 250 mg twice daily
Trial: 11789262
Drug: Composite Taixian
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composite Taixian tablet (CTXT)
Trial: 11789262
Drug: Tripterygium hypoglaucum
RxNorm normalized name: Tripterygium wilfordii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium hypoglaucum tablet
Trial: 11789262
Drug: Polyactin‐A tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyactin‐A tablet
Trial: 9081688
Drug: 2 mg/d
RxNorm normalized name: Uceris, 2 mg/dose rectal foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/d micronized 17 beta-estradiol
Trial: 1608523
Drug: Defibrotide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (400 mg bid im starting one day before surgery and continuing until the 7th postoperative day)
Trial: 1608523
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin (5000 IU bid sc starting two hours before surgery and continuing likewise for 7 days)
Trial: 3936097
Drug: Valerian extract
RxNorm normalized name: valerian extract
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian extract (450 mg)
Trial: 3936097
Drug: Valerian extract
RxNorm normalized name: valerian extract
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian extract (900 mg)
Trial: 31164265
Drug: Letrozole (L)
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole (L) vs Tamoxifen (T)
Trial: 31164265
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZL) vs Letrozole (L)
Trial: 29874375
Drug: Oxaliplatin followed
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin followed by TME and adjuvant chemotherapy (experimental arm)
Trial: 31283920
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT screening (LDCT)
Trial: 18710726
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus placebo, oxybutynin, or bladder training with online feedback (urge syndrome)
Trial: 18710726
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus pelvic floor training with online feedback (dysfunctional voiding)
Trial: 18710726
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (urge syndrome and dysfunctional voiding)
Trial: 15972357
Drug: Disease-modifying anti-rheumatic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-modifying anti-rheumatic drug (DMARD) therapy
Trial: 12133434
Drug: 6-MWT exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-MWT exercise training (twice a day for 8 weeks)
Trial: 12133434
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine medication only)
Trial: 10613616
Drug: HRT (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (2 mg estradiol valerate and 0.25 mg levonorgestrel once daily)
Trial: 7784306
Drug: Brand 1
RxNorm normalized name: Select Brand 12-Hour 0.05% Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand 1 (Biltricide) at full dose (40 mg kg‐1)
Trial: 7784306
Drug: Brand 2
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand 2 (Distocide) at full dose (40 mg kg‐1)
Trial: 7784306
Drug: Brand 1
RxNorm normalized name: Select Brand 12-Hour 0.05% Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand 1 (Biltricide) at half dose (20 mg kg‐1)
Trial: 7784306
Drug: Brand 2
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand 2 (Distocide) at half dose (20 mg kg‐1)
Trial: 2019862
Drug: Cefodizime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefodizime (2 g, once a day, i.v.)
Trial: 2019862
Drug: Norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (400 mg, twice a day, p.o.)
Trial: 6924538
Drug: Two-week amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-week amoxicillin treatment (250 mg three times a day)
Trial: 21319291
Drug: Opioids treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioids treatment
Trial: 21319291
Drug: Vincristine dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine dose
Trial: 17972431
Drug: Daily Mutual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Mutual Caring Interactions (DMCI) scale
Trial: 7938234
Drug: Phenylalanine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylalanine (up to 10.08 g)
Trial: 7938234
Drug: Aspartame (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (high doses)
Trial: 3203045
Drug: Nisoldipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (5 mg day-1)
Trial: 3203045
Drug: Nisoldipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (10 mg day-1)
Trial: 31313402
Drug: XR-NTX injection
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR-NTX injection every 4 weeks
Trial: 31313402
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection every 4 weeks
Trial: 28410787
Drug: 0.2% NTG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% NTG ointment applied at the anal canal twice daily for 8 weeks
Trial: 28410787
Drug: Classical conservative
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical conservative therapy (sitz bath, stool softener, local anesthetic)
Trial: 26180222
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received 8 weeks of nicotine replacement therapy (NRT) patch
Trial: 23549909
Drug: OM 40/AML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM 40/AML 10/HCTZ 25 mg triple-combination treatment
Trial: 18349202
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of dexamethasone i.v. before surgery
Trial: 10981070
Drug: Dihydropyridine calcium-channel
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydropyridine calcium-channel blockers
Trial: 8877026
Drug: Fluconazole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (150 mg)
Trial: 8877026
Drug: Co-trimoxazole (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (800 mg sulphamethoxazole and 160 mg trimethoprim)
Trial: 29650949
Drug: Monoclonal IgG
RxNorm normalized name: Monoclonal IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal IgG antibodies against Fel d 1 (single dose)
Trial: 24714359
Drug: Erlotinib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib therapy
Trial: 18377647
Drug: Eurythmy therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eurythmy therapy (EYT) as an add-on treatment
Trial: 16153010
Drug: Theophylline ethanoate
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline ethanoate of piperazine suppositories (Minophylline 500 mg)
Trial: 16153010
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) theophylline ethanoate of piperazine (Minophylline ampoules 500 mg)
Trial: 8697058
Drug: Sibutramine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 20 mg/day
Trial: 8911510
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with ALT
Trial: 26993261
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of renal replacement therapy
Trial: 26993261
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of renal replacement therapy
Trial: 24332419
Drug: Newer-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer-generation drug-eluting stents (everolimus-eluting stent or biolimus A9-eluting stent)
Trial: 20375277
Drug: Low anticoagulant
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low anticoagulant 2-O,3-O-desulfated heparin (ODSH)
Trial: 17493184
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care provided from admission to discharge by a specialist clinical pharmacist
Trial: 11486702
Drug: Cyclophosphamide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 600 mg/m2 plus carboplatin 300 mg/m2 (conventional dose)
Trial: 11486702
Drug: Cyclophosphamide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 600 mg/m2 plus carboplatin 600 mg/m2 (intensive dose)
Trial: 31465092
Drug: AAV2-REP1 gene
RxNorm normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV2-REP1 gene therapy (0.1-mL subretinal injection of 10^11 genome particles)
Trial: 24954781
Drug: Sequential chemoimmunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemoimmunotherapy (chemotherapy with sequential GV1001)
Trial: 24954781
Drug: Concurrent chemoimmunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoimmunotherapy (chemotherapy with concurrent GV1001)
Trial: 22224877
Drug: Community-focused interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-focused interventions (e.g., school-based programs, community coalitions)
Trial: 19008007
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG) therapy
Trial: 19008007
Drug: Rosiglitazone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone plus insulin (INS+RSG)
Trial: 19008007
Drug: Insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin alone (INS)
Trial: 15500597
Drug: Buprenorphine (58
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (58 mg subcutaneous depot injection)
Trial: 10667832
Drug: Dexibuprofen 400
RxNorm normalized name: Dexibuprofen 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexibuprofen 400 mg t.i.d.
Trial: 10667832
Drug: Racemic ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Racemic ibuprofen 800 mg t.i.d.
Trial: 11771571
Drug: Racemic ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Racemic ibuprofen 2400 mg daily
Trial: 22611313
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein supplementation (32 g/d for 12 weeks)
Trial: 22611313
Drug: Casein supplementation
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein supplementation (control group, 32 g/d for 12 weeks)
Trial: 8857632
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (NTG) 5-mg patch per day over 3 days
Trial: 3330182
Drug: Sublingual prazepam
RxNorm normalized name: prazepam
DrugBank: Prazepam (DB01588)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual prazepam
Trial: 3330182
Drug: Oral prazepam
RxNorm normalized name: prazepam
DrugBank: Prazepam (DB01588)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prazepam
Trial: 27716293
Drug: TNT009, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNT009, a humanized monoclonal antibody directed against the C1s subunit of human complement component C1, administered in a double-blind, randomized, placebo-controlled manner.
Trial: 22882646
Drug: Metronidazole (MTZ)
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole (MTZ) 400 mg/TID and Amoxicillin (AMX) 500 mg/TID for 14 days
Trial: 20073214
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy with Premarin 0.625 g, once daily by oral taking
Trial: 8182900
Drug: Fluconazole (FLCZ)
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole (FLCZ) administered intravenously at a dosage of 3 mg/kg
Trial: 8182900
Drug: Fluconazole (FLCZ)
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole (FLCZ) administered orally
Trial: 8182900
Drug: Fluconazole (FLCZ)
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole (FLCZ) administered intravenously
Trial: 3235820
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) at several doses
Trial: 26558293
Drug: Stem cell
RxNorm normalized name: Stem cells, apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stem cell therapy (mesenchymal stem cells and neural fetal stem cells)
Trial: 23725917
Drug: CoQ10 supplementation
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 supplementation (600 mg daily)
Trial: 20642205
Drug: 1.5% bepotastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% bepotastine besilate ophthalmic solution
Trial: 18377661
Drug: Cissus quadrangularis/Irvingia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cissus quadrangularis/Irvingia gabonensis combination
Trial: 31025274
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (anti-PD-1 and anti-CXCR4)
Trial: 24504098
Drug: Aganirsen (0.86
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aganirsen (0.86 mg/g)
Trial: 24504098
Drug: Aganirsen (1.72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aganirsen (1.72 mg/g)
Trial: 22873635
Drug: In sequence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In sequence computer tutorial (e.g. FWS patient + FWS tutorial)
Trial: 22873635
Drug: Out-of-sequence computer
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Out-of-sequence computer tutorial (e.g. FWS patient + ORS tutorial)
Trial: 17118996
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg iodine as oral iodized oil
Trial: 17118996
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg iodine as oral iodized oil (two doses)
Trial: 12164886
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (optimal doses of lisinopril and losartan)
Trial: 10204938
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of morphine (1 ml) and 9 ml of saline
Trial: 10204938
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of bupivacaine (2.5 mg/ml)
Trial: 10204938
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of morphine (1 ml) and 9 ml of bupivacaine (2.5 mg/ml)
Trial: 2155948
Drug: conventional metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional metoprolol 100 mg
Trial: 7006073
Drug: Vaccinated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated with intact influenza vaccine
Trial: 27406943
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of enteral nutrition formulas (2 different formulas)
Trial: 27406943
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g lactulose
Trial: 21516022
Drug: IV anti-D
RxNorm normalized name: anti-D (rh) immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV anti-D (50 μg/kg)
Trial: 21516022
Drug: IVIG (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (0.8 to 1 g/kg)
Trial: 19920236
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (0.8 mg/d) plus vitamin B(12) (0.4 mg/d)
Trial: 16972106
Drug: d-amphetamine 0
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine 0 mg/70 kg (placebo)
Trial: 14740785
Drug: Intranasal hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal hydromorphone hydrochloride after 6 days of fluticasone propionate (treatment C)
Trial: 14740785
Drug: Intranasal hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal hydromorphone hydrochloride without allergic rhinitis treatment (treatment B)
Trial: 14740785
Drug: Intravenous hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydromorphone hydrochloride 2.0 mg (treatment A)
Trial: 14740785
Drug: Intranasal treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal treatments (B and C)
Trial: 14740785
Drug: Intranasal hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal hydromorphone hydrochloride
Trial: 3010011
Drug: Oral nabilone
RxNorm normalized name: Nabilone
DrugBank: Nabilone (DB00486)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nabilone (1 mg 8 hourly)
Trial: 3010011
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide (1 mg kg‐1 3 hourly)
Trial: 24901089
Drug: SDF (oat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDF (oat β‐glucan 7.5 g, 500 mL, 500 Kcal)
Trial: 22830971
Drug: Milled chia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milled chia seed (25 g/day for 10 weeks)
Trial: 22830971
Drug: Whole chia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole chia seed (25 g/day for 10 weeks)
Trial: 22830971
Drug: Placebo (poppy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (poppy seed, 25 g/day for 10 weeks)
Trial: 17461474
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg twice daily) and Domperidone (10 mg three times daily)
Trial: 16036039
Drug: Statins (3‐Hydroxy‐3‐methylglutaryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins (3‐Hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors)
Trial: 12113287
Drug: 800 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day alpha-tocopherol supplementation
Trial: 2800995
Drug: Ketamine 10
RxNorm normalized name: ketamine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 10 mg.kg‐1 BW and midazolam 0.2 mg.kg‐1 BW for induction with intravenous ketamine for maintenance
Trial: 2800995
Drug: Ketamine 10
RxNorm normalized name: ketamine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 10 mg.kg‐1 BW and midazolam 0.2 mg.kg‐1 BW for induction with halothane for maintenance
Trial: 30796528
Drug: Stepped Collaborative
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepped Collaborative Care Model (SCCM) including group-level interventions (START intervention, Empowerment/Gender-sensitive/Peer to peer) and digital treatment approaches (Smartphone application)
Trial: 29199566
Drug: High-dose supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose supplement (HD) group
Trial: 29199566
Drug: Low-dose supplement
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose supplement (LD) group
Trial: 22276649
Drug: Conventional resin-based
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional resin-based sealant with Er:YAG + AE preparation technique
Trial: 21190996
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (HiDAC, 2 g/m(2) twice daily for 5 days)
Trial: 21190996
Drug: Multiagent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiagent chemotherapy (CT)